No connection

Search Results

Corporate Score 35 Bullish

Can-Fite BioPharma Reports Positive Phase 2a Results for Pancreatic Cancer Treatment

Apr 30, 2026 14:20 UTC
CANF
Short term

Can-Fite BioPharma has announced encouraging data from its Phase 2a trial of namodenoson. The drug demonstrated disease stability in over 30% of evaluable patients with advanced pancreatic cancer.

  • Over 30% of evaluable patients showed stable disease
  • Approximately 35% of patients remain on therapy
  • One patient achieved treatment duration exceeding 16 months
  • Shares rose 14.72% to $3.43 following the news
  • Detailed survival data expected in coming months

Can-Fite BioPharma Ltd. (CANF) has released positive results from its Phase 2a clinical trial evaluating namodenoson, a therapeutic candidate targeting advanced pancreatic cancer. The study focused on a patient population that had previously undergone multiple lines of treatment, making the observed stability results particularly notable for this difficult-to-treat malignancy. According to the company, more than 30% of evaluable patients achieved stable disease. The data suggests potential for lasting benefits, as approximately 35% of the patients are still receiving therapy. In one specific case, a patient remained on the treatment for more than 16 months. Following the announcement, CANF shares rose 14.72% to $3.43 on the New York Stock Exchange. The company indicated that it intends to share more comprehensive efficacy data, including specific survival rates, in the coming months. This development marks a significant milestone for the company's oncology pipeline, although the results remain preliminary pending the release of the full data set.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI Chat
Markets
Profile